Literature DB >> 15537517

Cerebral amyloid angiopathy and gene polymorphisms.

Masahito Yamada1.   

Abstract

Cerebral amyloid angiopathy (CAA) is characterized by cerebrovascular amyloid deposition, associated with intracerebral hemorrhage and other cerebrovascular disorders and dementia. Several types of CAA have been identified in association with various amyloid proteins including amyloid beta protein (Abeta), cystatin C, prion protein, ABri/ADan, transthyretin, and gelsolin. Hereditary forms of CAA are associated with mutations in the genes coding these proteins or their precursors. Sporadic CAA of Abeta type is most common in elderly individuals as well as patients with Alzheimer disease (AD). Several gene polymorphisms have been reported to be associated with sporadic CAA or CAA-related hemorrhage, including apolipoprotein E (APOE), presenilin 1 (PS1), and alpha1-antichymotrypsin (ACT). As for the APOE, which has been well studied for CAA as well as AD and Abeta deposition, the epsilon4 allele is found to be associated with CAA, and the epsilon2 with CAA-related hemorrhage. Recently, we investigated whether gene polymorphisms of neprilysin (NEP), an Abeta-degrading enzyme, and the transforming growth factor (TGF)-beta1 (TGF-beta1), a multifunctional cytokine implicated in Abeta deposition, are associated with sporadic CAA. Concerning a GT repeat polymorphism in the enhancer/promoter region of the NEP, the shorter repeat alleles were associated with the CAA severity. The T/C polymorphism at codon 10 in exon 1 of the TGF-beta1 was also associated with the severity of CAA. These data suggest that multiple gene polymorphisms, including molecules related to the Abeta cascade, could be associated with the risk of sporadic CAA.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15537517     DOI: 10.1016/j.jns.2004.09.009

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  12 in total

Review 1.  Genetics of stroke.

Authors:  Jin-min Guo; Ai-jun Liu; Ding-feng Su
Journal:  Acta Pharmacol Sin       Date:  2010-08-23       Impact factor: 6.150

Review 2.  Targeting amyloid clearance in Alzheimer's disease as a therapeutic strategy.

Authors:  Natalia N Nalivaeva; Anthony J Turner
Journal:  Br J Pharmacol       Date:  2019-03-11       Impact factor: 8.739

Review 3.  Aging and cerebrovascular dysfunction: contribution of hypertension, cerebral amyloid angiopathy, and immunotherapy.

Authors:  Vitaly Vasilevko; Giselle F Passos; Daniel Quiring; Elizabeth Head; Richard C Kim; Mark Fisher; David H Cribbs
Journal:  Ann N Y Acad Sci       Date:  2010-10       Impact factor: 5.691

4.  Amyloid-Related Imaging Abnormalities with Emerging Alzheimer Disease Therapeutics: Detection and Reporting Recommendations for Clinical Practice.

Authors:  P M Cogswell; J A Barakos; F Barkhof; T S Benzinger; C R Jack; T Y Poussaint; C A Raji; V K Ramanan; C T Whitlow
Journal:  AJNR Am J Neuroradiol       Date:  2022-08-11       Impact factor: 4.966

5.  Thermodynamic and structural characterization of an antibody gel.

Authors:  Osigwe Esue; Anna X Xie; Tim J Kamerzell; Thomas W Patapoff
Journal:  MAbs       Date:  2013-02-20       Impact factor: 5.857

6.  Predicting cerebral amyloid angiopathy-related intracerebral hemorrhages and other cerebrovascular disorders in Alzheimer's disease.

Authors:  Masahito Yamada
Journal:  Front Neurol       Date:  2012-04-25       Impact factor: 4.003

7.  A Chronic Fatigue Syndrome - related proteome in human cerebrospinal fluid.

Authors:  James N Baraniuk; Begona Casado; Hilda Maibach; Daniel J Clauw; Lewis K Pannell; Sonja Hess S
Journal:  BMC Neurol       Date:  2005-12-01       Impact factor: 2.474

Review 8.  Cerebral microbleeds: a review of clinical, genetic, and neuroimaging associations.

Authors:  Paul A Yates; Victor L Villemagne; Kathryn A Ellis; Patricia M Desmond; Colin L Masters; Christopher C Rowe
Journal:  Front Neurol       Date:  2014-01-06       Impact factor: 4.003

Review 9.  Cerebral amyloid angiopathy: emerging concepts.

Authors:  Masahito Yamada
Journal:  J Stroke       Date:  2015-01-30       Impact factor: 6.967

10.  A drastic reduction in the life span of cystatin C L68Q carriers due to life-style changes during the last two centuries.

Authors:  Astridur Palsdottir; Agnar Helgason; Snaebjorn Palsson; Hans Tomas Bjornsson; Birkir Thor Bragason; Solveig Gretarsdottir; Unnur Thorsteinsdottir; Elias Olafsson; Kari Stefansson
Journal:  PLoS Genet       Date:  2008-06-20       Impact factor: 5.917

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.